

In the Specification:

Rewrite the paragraph at page 10, lines 6-9, to read as follows:

Q1 (amended) Fig. 2 shows the concentration-dependent inhibition of endothelial cell proliferation by HK_a (fine crosshatched bars), HK (white bars) and low molecular weight kininogen (course crosshatched bars). Low molecular weight kininogen is non-inhibitory.

Rewrite the paragraph at page 10, lines 15-19, to read as follows:

Q2 (amended) Fig. 5 shows the inhibition of endothelial cell proliferation as a function of HK_a concentration and cell density in the culture. White bars = 1,500 cells/well; course crosshatched bars = 3,000 cells/well; fine crosshatched bars = 6,000 cells/well; very fine crosshatched bars = 12,000 cells/well; vertically hatched bars = 24,000 cells/well.

Rewrite the paragraph at page 20, lines 21, to read as follows:

Q13
$$\% \text{ inhibition} = (1 - [(A_{490} (+GF, HK_a) - A_{490} (-GF)) / (A_{490} (+GF) - A_{490} (-GF))]) \times 100,$$

In the Claims:

Cancel claims 5-7, 10-15, 17, 18, 20, 21 and 23-29, without prejudice.

Rewrite claims 1, 16 and 32 to read as follows.

Q4 1. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X₁-His-Lys-X-Lys-X₂ wherein

X is any amino acid,

X₁ is the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and

X₂ is

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid,

and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

16. (Amended) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X₁-His-Lys-X-Lys-X₂ wherein

X is any amino acid,

X₁ is from zero to twelve amino acids, and

X₂ is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal protecting and optionally comprises a carboxy-terminal protecting group.

32. (amended) The compound of claim 30 having at least about 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).